Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 5/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16987358 | 1.00 | RORC (0.54) | RORCKDM1ATACR1NAMPTJAK2 | |
| SCHEMBL15411988 | 0.92 | RORC (0.48) | RORCKDM1ATACR1NAMPTJAK2 | |
| SCHEMBL15411990 | 0.92 | RORC (0.48) | RORCKDM1ATACR1NAMPTJAK2 | |
| SCHEMBL19609098 | 0.91 | KDM1A (0.56) | RORCKDM1ATACR1NAMPTNR1H2 | |
| SCHEMBL12832564 | 0.90 | KDM4E (0.48) | RORCKDM1ATACR1NAMPTJAK2 | |
| SCHEMBL15410432 | 0.90 | KDM4E (0.48) | RORCKDM1ATACR1NAMPTJAK2 | |
| SCHEMBL16995586 | 0.89 | RORC (0.52) | RORCKDM1ATACR1NAMPTJAK2 | |
| SCHEMBL16989520 | 0.85 | KDM1A (0.53) | RORCKDM1AJAK2JAK1 | |
| SCHEMBL16989521 | 0.85 | KDM1A (0.53) | RORCKDM1AJAK2JAK1 | |
| SCHEMBL16989496 | 0.85 | KDM1A (0.46) | RORCKDM1AJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2021-10-26 | — | — | US | disclosed |
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-01-28 | — | — | US | disclosed |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-01-28 | — | — | US | disclosed |
| US-20170121302-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-20170121302-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-9527835-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2016-12-27 | — | — | US | disclosed |
| EP-3105218-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9493450-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2015123465-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123465-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225375-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225394-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | RORC 1607/4885KDM1A 2/4885TACR1 3885/4885 |
| US-20150225375-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | RORC 1607/4885KDM1A 2/4885TACR1 3885/4885 |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | RORC 1607/4885KDM1A 2/4885TACR1 3885/4885 |
| US-20170121302-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | RORC 1607/4885KDM1A 2/4885TACR1 3885/4885 |
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | RORC 1607/4885KDM1A 2/4885TACR1 3885/4885 |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | RORC 1607/4885KDM1A 2/4885TACR1 3885/4885 |
| US-20150225394-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | RORC 1607/4885KDM1A 2/4885TACR1 3885/4885 |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | RORC 1607/4885KDM1A 2/4885TACR1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.